BEAM THERAPEUTICS INC.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

02 дек 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

30 ноя 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

14 ноя 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming Investor Conferences

09 ноя 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

07 ноя 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting

03 ноя 2022 08:01:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection

19 сен 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

01 сен 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

09 авг 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

02 авг 2022 07:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

27 июн 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

03 июн 2022 05:42:39 Источник Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

09 май 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

04 май 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

25 мар 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

08 мар 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

28 фев 2022 05:30:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

09 фев 2022 05:30:00 Источник Nasdaq GlobeNewswire

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

10 янв 2022 05:00:00 Источник Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

09 янв 2022 08:00:00 Источник Nasdaq GlobeNewswire